Habib Hadianfard MD, 2 Nahid Ashjazadeh MD, 1 Soodabe Feridoni BS, 1 Elham Farjam BS



Similar documents
International Journal of Economics, Commerce and Management United Kingdom Vol. II, Issue 2, 2014

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

Global Economic Impact of Multiple Sclerosis

1695 N.W. 9th Avenue, Suite 3302H Miami, FL Days and Hours: Monday Friday 8:30a.m. 6:00p.m. (305) (JMH, Downtown)

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

Satisfaction with Life after Spinal Cord Injury: A look over 35 years. Stephanie Kolakowsky-Hayner, PhD Kimberly Bellon Jerry Wright, MS

Original Article. Annals of Rehabilitation Medicine INTRODUCTION

AbolfazlMohammadi, PhD.

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute

ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate

Diagnosis communication and patients coping strategies. Dawn Langdon PhD

MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION

DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource

Accuracy in Space and Time: Diagnosing Multiple Sclerosis Genzyme Corporation, a Sanofi company.

Clinical Study Synopsis

Robert Okwemba, BSPHS, Pharm.D Philadelphia College of Pharmacy

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest

Frequent headache is defined as headaches 15 days/month and daily. Course of Frequent/Daily Headache in the General Population and in Medical Practice

Spinal cord injury and quality of life: a systematic review of outcome measures

Executive Summary. 1. What is the temporal relationship between problem gambling and other co-occurring disorders?

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Specialty Drug Care: Case management services in Quebec

Extended Abstract. Evaluation of satisfaction with treatment for chronic pain in Canada. Marguerite L. Sagna, Ph.D. and Donald Schopflocher, Ph.D.

What is Multiple Sclerosis? Gener al information

How To Use A Drug In Multiple Sclerosis

The Effect of Physical Exercise on Depression; Case study: Professional and Nonprofessional

Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December Reference : NHSCB/D4/c/1

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

Life with MS: Mastering Early Treatment

practitioners and physician assistants.advanceweb.com/features/articles/alcohol Abuse.aspx

New perception of disability including cognition, fatigue, pain and other impairments related to MS

PhD. IN (Psychological and Educational Counseling)

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Fatigue in MS: 2005 update B. Colombo University of Milan - HSR

Deirdre Dlugonski East Carolina University 160 Minges Coliseum

Courses Description Bachelor Degree in Social Work

Under the Start Your Search Now box, you may search by author, title and key words.

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

indicates that the relationship between psychosocial distress and disability in patients with CLBP is not uniform.

Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role

Objectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons.

Recommendations for Rehabilitation in People with MS Thomas Henze, Nittenau / Germany

Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015

Effectiveness of Training Positive Thinking Skills Mental Health of Self- Represented Clients in Addiction Treatment Centers of Welfare

Administration of Emergency Medicine

How To Cover Occupational Therapy

INVESTIGATING THE EFFECTIVENESS OF POSITIVE PSYCHOLOGY TRAINING ON INCREASED HARDINESS AND PSYCHOLOGICAL WELL-BEING

Personality traits in multiple sclerosis: association with mood and anxiety disorders in a Romanian patients sample

Psychology. Academic Requirements. Academic Requirements. Career Opportunities. Minor. Major. Mount Mercy University 1

World Scientific News

College of Education. Rehabilitation Counseling

Master of Arts in Psychology: Counseling Psychology

A User's Guide to: Rheumatoid and Arthritis Outcome Score RAOS

Evaluation of the Relationship between Personality Characteristics and Social Relations and the Environmental Life Condition in Addicts

The ACC 50 th Annual Scientific Session

Objectives. Significant Costs Of Chronic Pain. Pain Catastrophizing. Pain Catastrophizing. Pain Catastrophizing

Psychology Externship Program

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Depression & Multiple Sclerosis. Managing Specific Issues

Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria

AUBMC Multiple Sclerosis Center

Depression often coexists with other chronic conditions

Supplementary appendix

The relationship between family function and the quality of life in people with MS and normal people.

Department of Psychiatry, The University of Melbourne

The relationship between mental wellbeing and financial management among older people

Disease Modifying Therapies for MS

Health-related quality of life in multiple sclerosis patients with bladder, bowel and sexual dysfunction

Psychology PhD / MA. Ryerson University, 350 Victoria Street, Toronto, ON M5B 2K3 Canada October 2009 (65967)

Natalizumab (Tysabri)

Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment

Patricia Beldotti, Psy.D. Tel: Web:

Post Traumatic Stress Disorder (PTSD) Karen Elmore MD Robert K. Schneider MD Revised by Robert K. Schneider MD

R ating scales are consistently used as outcome measures

Alcohol Overuse and Abuse

Complementary and alternative medicine use in Chinese women with breast cancer: A Taiwanese survey

Information for Applicants

November 15, Ann Laramee MS ANP-BC ACNS-BC CHFN FletcherAllen.org

TECHNICAL/CLINICAL TOOLS BEST PRACTICE 7: Depression Screening and Management

CARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS

Applied Psychology. Course Descriptions

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary

LONG TERM HYPERBARIC OXYGENATION (HBO) RETARDS PROGRESSION IN MULTIPLE SCLEROSIS PATIENTS

Transcription:

Neurology Asia 2015; 20(3) : 263 268 The role of psychological resilience, severity of disease and treatment adherence in the prediction of health-related quality of life in patients with multiple sclerosis 1 Habib Hadianfard MD, 2 Nahid Ashjazadeh MD, 1 Soodabe Feridoni BS, 1 Elham Farjam BS 1 Department of Clinical Psychology, Shiraz University, Shiraz; 2 Shiraz Neuroscience Research Center, Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran Abstract Objective: This cross-sectional study aims to evaluate the impact of the disability status, psychological resilience, and treatment adherence on health-related quality of life (QOL) in patients with multiple sclerosis (MS). Methods: One hundred MS outpatients, 80 women and 20 men, referred to a clinic of Shiraz University of Medical Sciences, were eligible to participate. MS was diagnosed by 2010 revised Mc-Donald criteria. The QOL and resilience were evaluated by the Medical Outcomes Study Short-Form (SF-36) and Connor-Davidson Resilience Scale (CD-RISC) respectively. Medication adherence and severity of disease were assessed by the Morisky Medication Adherence Scale (MMAS) and expanded disability status state (EDSS) scores respectively. Results: Stepwise multiple regressions showed that in the first model, the disability status was the best predictor which accounted for 28.1% of the variance in QOL. In the second model, both the disability status and resilience explained 50.6% of the variation in QOL. Conclusion: The findings showed that the severity of the disease is a strong predictor which has adverse effects on the physical component of health-related QOL in the patients with MS. Both psychological resilience and treatment adherence have positive influence on mental component of QOL in these patients. INTRODUCTION Multiple sclerosis (MS) is a common neurologicaldisorder which mostly affects the active adult population. 1 Distribution and severity of demyelinating and degenerative lesions in the brain and spinal cord of these patients are associated with a variety of symptoms which can impact adversely on the health-related quality of life (QOL) in these patients. Both somatic symptoms such as weakness, spasticity, pain and non-somatic ones such as affective and cognitive impairments have a negative influence on different domains of QOL. 1-4 Discovery and development of several types of disease modifying drugs changes the disabling course of MS by reducing relapses and slowing disease progression. 5 However, similar to other chronic diseases, treatment adherence is a common problem and it has been shown that cases with good adherence suffer from fewer relapses and have better QOL compared with poor adherence cases. 6-8 Psychological resilience is the patients ability to properly adapt and cope with her/his disease which has a positive role in QOL of patients. 9,10 Treatment adherence problems and disability status have a negative effect on QOL 1,11, while psychological resilience has a positive impact on QOL in patients with MS. 3 This study aims to assess the impact of adherence to treatment, severity of illness, and psychological resilience on the health-related QOL inthe Iranian patients with MS. The hypothesis of this study is that there is a significant correlation between psychological resilience, adherence to treatment, and expanded disability status of patients with MS and their physical and mental components of health-related QOL. METHODS We performed a descriptive, study, using multiple regressions. Three predictor variables, including resilience, treatment adherence and severity of sickness, were used and QOL was considered Address correspondence to: Dr. Nahid Ashjazadeh, Shiraz Neuroscience Research Center, Chamran Hospital, Chamran Boulevard, Shiraz, Iran. PO Box: 7194815644, Tel: +9871-36234508, Fax: +9871-36234508, E-mail: nashjazadeh@yahoo.com, neuroscien@sums.ac.ir 263

Neurology Asia September 2015 as a dependent variable. Data collection was undertaken between August 2012 and March 2013. The participants were interviewed by a research assistant before completing the questionnaires. All the participants were volunteers who were informed about objectives and method of the study and signed a written consent form. The Research Ethics Committee of Shiraz University of Medical Sciences approved the protocol of this study (approval number: 90-4120). All the stages of the present research were conducted according to Psychology and Counselling Organization of I. R. Iran s ethics codes. One hundred patients, aged 17 to 64 years, with MS who referred to the clinics affiliated to Shiraz University of Medical Sciences between August 2012 and March 2013 were included in the study. The patients were selected using convenience sampling method. Individuals with a confirmed diagnosis of MS, who were above 16 years old, were included in the study. The patients who had co-morbidities such as cancer, renal failure, other chronic diseases and major psychological problems were excluded from the study. MS was diagnosed by a neurologist according to the neurologic examination and imaging data using 2010 revised Mc-Donald criteria. 12 Measurement The patients completed a medical and demographic information form and then they filled out three other research questionnaires. Medical Outcomes Study Short-Form (SF-36): SF-36 is a commonly used self-reporting tool for assessing health-related QOL. 13 Questions cover eight domains which can be summarized into two overall subscales, physical component and mental component, which score in each domain ranging from 0 to 100 that the highest scores correspond to a healthier status. We used Persians form of SF-36 whose reliability and validity has been demonstrated. 14 Connor-Davidson Resilience Scale (CD-RISC): CD-RISC was developed to measure stress coping ability. CD-RISC can range in score from 0 to 100 and higher scores reflect better resilience. The authors reported good psychometric properties of the scale. 15 Mohammadi 16 showed that the reliability and validity of the Persian form was good. 17 Morisky Medication Adherence Scale (MMAS): MMAS is one of the most frequently used selfreporting methods to determine medication-taking behavior. The range of adherence can be variable from 0 to 8. The higher test scores reflect the better medical adherence. Previous investigators have reported a good reliability (α=0.83) for the scale, they also showed acceptable concurrent and predictive validity. 18 The investigator of Persian form also found sufficient internal consistency (Cronbach s α = 0.89); the Persian version of the scale is reliable and valid. 19 Expanded Disability Status Scale (EDSS): Kurtzke s EDSS 20 is a standard method of evaluating the degree of progressive physical disability in MS. It converts the disease severity to an ordinal scale which has 20 steps ranging from 0 (normal neurological exam) to 10 (death due to MS). 20 In the present study, EDSS was assessed for all the patients by a single neurologist. After entering the data into SPSS software, descriptive methods and multivariate regression were applied to test the hypothesis. The ANOVA and independentt testwere used to analyse the differences between the groups. All P values less than 0.05 were considered statistically significant. RESULTS One hundred patients, 80 women and 20 men, were enrolled for participation in this study according to the inclusion criteria. The patients mean age was 35.15 ± 9.56 year. The demographic characteristics of the patients are shown in Table 1. The means and (standard deviations) for resilience, disability status and medication adherence scales are shown in Table 2. Men experienced significantly more severe disability status than women. Descriptive statistics for the total score, physical component and mental component of the SF-36 are shown in Table 2. The scores of women were slightly and non-significantly higher than that of men so it was not entered as a predictor in multivariate analyses. Using a one-way analysis of varianceon the SF-36 total score showed that there was no statistically significant difference between marital status (P>0.05). Therefore, we did not enter marital status as predictors in stepwise regression. The results revealed that the resilience (r=.515, P=.000) and medication adherence (r=.316, P=.001) were positively correlated with QOL, however, the disability status (r=-.53, P=.000) was negatively correlated with QOL. 264

Table 1: Demographic characteristics of the patients Total subjects n=100 Gender (%) Man 20 Woman 80 Age (%) <20 1 20 to 30 40 31 to 40 26 41 to 50 28 >50 5 Education (%) Primary school 30 High school 38 Undergraduate 31 Postgraduate 1 Marriage status (%) Single 27 Married 69 Divorced 4 Job status (%) Employed 30 Unemployed 70 A stepwise linear regression was used to test the main hypothesis. Scores of resilience, medication adherence and EDSS were used as candidate variables in the stepwise to predict SF-36 total scores (QOL). Stepwise regression showed that in the first model, disability status was the best predictor for the dependent variable. As Table 3 shows, disability status accounted for 28.1% of the variance in QOL. In the second model, the disability status and resilience together explained 50.6% of the variation in QOL. Our results revealed that, out of all three predictors, only two of them significantly predicted QOL. Medication adherence was not a good predictor after including disability status and resilience in the regression. A stepwise linear Table 2: The means and standard deviations of independent variables Variables Women Men All respondents t value P value Resilience Scale 65.13 66.55 65.41 (20.20) (14.32) (19.10) Medication Adherence Scale 5.46 5.75 5.52 (2.09) (1.38) (2.04) Disability Status Scale 2.27 2.97 2.41 (1.79) (2.31) (1.97) Total score of SF36 59.080 57.144 57.531 (22.16) (27.87) (23.27) Physical component 60.716 59.175 59.484 (24.05) (27.47) (24.63) Mental component 52.354 48.491 49.263 (22.00) (27.70) (23.15) 0.29 NS 0.56 NS 1.47.02 0.331 NS 0.249 NS 0.665 NS NS, Not significant 265

Neurology Asia September 2015 regression analysis was conducted to evaluate the first sub-hypothesis and to determine whether resilience, medication adherence and EDSS would predict the physical component of QOL. Table 3 indicates that the disability status predicted 30.2% of the variance of the physical component of QOL. In the second step, the disability status and resilience simultaneously explained 47% of the variation in QOL. The beta coefficients showed that the correlation between disability status and physical component was stronger than other predictors. Once more, a stepwise linear regression analysis was applied to test the second sub-hypothesis and to ascertain which independent variables predict the mental component of QOL. As shown in Table 3, resilience was the best predictor of mental component and it predicted 25.9% of variation in the dependent variable. In the second model, a combination of resilience and disability status mutually predicted 34% of the mental component variation. Medication adherence was the weakest independent variable that was excluded for prediction of mental components. The result indicated that the predicted mental components were associated with increased resilience (positive beta coefficient). Disability status was associated with decreased mental components (negative beta coefficient). DISCUSSION The results of the regression analysis indicated that disability status was negatively associated with QOL. Disability status was a stronger predictor of QOL than the resilience and medical adherence. Disability status displayed strong and statistically significant negative associations with both QOL and physical component of QOL. Several studies in the area of health-related QOL have shown that physical disability has an important role in determining QOL. Murphy et al. 2 evaluated 90 patients with MS from France, Germany and United Kingdom using EDSS and reported that there was a significant correlation between severity of MS and both physical and social function of their patients. However, they did not find a correlation between disease severity and psychological function. Their finding and our result are largely due to the nature of EDSS scores which mostly measure the physical ability rather than mental function. There are other studies that support the negative effect of the disability status on QOL of patients with MS. 4,21 On psychosocial factors, psychological resilience had an important role in coping with chronic health conditions. Resilience is an ability that influenced by various factors, such as internal personality and external environments which determine an adjustment to health problem conditions 22 and may play a significant role in functional outcomes. 23 The findings of our study showed that the patients resilience was associated positively with QOL and its mental health component. In our study, the high resilience as a personality trait helped MS patients to reconstruct their cognition in order not to dramatize their disability and fatigability. Table 3: Results of the stepwise linear regression for predicting the quality of life and the coefficient of physical and mental components Model Predictors in the Model R R Square Adjusted R Std. Error of F P value Square the Estimate 1 (Constant), Disability status Quality of life.530.281.274 19.90045 37.559 <0.001 Physical component.550.302.295 20.78538 41.588 <0.001 2 (Constant), Disability status, Resilience Quality of life.712.506.496 16.57730 48.737 <0.001 Physical component.685.470.459 18.21586 42.071 <0.001 3 (Constant), Resilience status Mental components.509.259.251 20.20872 33.530 <0.001 (Constant), Resilience, Disability Status Mental components.585.342.328 19.14617 24.653 <0.001 266

The same result reported in other researches showed high psychological resilience negatively correlated with progressive of chronic illness. 24 On the one hand, cognitive reconstruction in a chain order may help MS patients not to give up easily in social and career challenges such as job performance and family relationships. 3 On the other hand, the patients with low resilience expected a threatening and less controllable life, making them feeling more depressed and helpless, resulting in inadequate response to their personal and social problems. 24 Although adherence to treatment have been associated with better outcome and lower mortality and morbidity in the patients with MS 7,11, in our study adherence to treatment was a weaker predictor of mental component of QOL compared to psychological resilience. This might be explained by the hypothesis that patients who had high psychological resilience had better adherence and these two variables are closely related. In conclusion, the severity of the disease, measured by EDSS, is a strong predictor in the patients with MS and has a negative effect on the physical component of the health-related QOL. Both psychological resilience and treatment adherence have a positive influence on the mental component of QOL in the patients with MS. Treatment strategies for reducing disability and an appropriate management for enhancing the psychological resilience can lead to treatment adherence and as a result to a better QOL. ACKNOWLEDGMENTS The authors would like to thank Ms. Hosseini and Ms. Gholami of Shiraz Neuroscience Research Center for their help. DISCLOSURE Financial support: None Conflict of interests: None REFERENCES 1. Motl RW, McAuley E. Symptom cluster and quality of life: preliminary evidence in multiple sclerosis. J Neurosci Nurs 2010; 42:212-6. 2. Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry 1998; 65:460-6. 3. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991; 41:692-6. 4. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49:1237-42. 5. Freedman MS, Hughes B, Mikol DD, et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur Neurol 2008; 60:1-11. 6. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to diseasemodifying therapies in patients with relapsingremitting multiple sclerosis. Eur J Neurol 2011; 18:69-77. 7. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100. 8. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009; 256:568-76. 9. Falk-Kessler J, Kalina JT, Miller P. Influence of occupational therapy on resilience in individuals with multiple sclerosis. Int J MS Care 2012; 14:160-8. 10. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci 2002; 205:51-8. 11. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence 2011; 5:73-84. 12. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292-302. 13. Ware JE Jr, Sherbourne CD. The MOS 36-item shortform health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-83. 14. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res 2005; 14:875-82. 15. Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety 2003; 18:76-82. 16. Mohammadi M. Understanding factors affecting resilience on individuals exposed to drug abuse. Tehran, Iran; University of Social Welfare and Rehabilitation Sciences, 2005. Dissertation. 17. Samani S, Jokar B, Sahragard N. Resiliency, psychological health and life satisfaction. Iran s Psychiatric and Clinical Psychology Magazine (in Persian) 2007; 13th year: 290-5. 18. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10:348-54. 19. Bakaeian M. Study of personality characteristics, 267

Neurology Asia September 2015 memory performance, demographic characteristics as predictive of adherence to treatment in heart patients. Shiraz, Iran; Shiraz University, 2012. Dissertation. 20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-52. 21. Freeman JA, Langdon DW, Hobart JC, Thompson AJ. Health-Related Quality of Life in people with multiple sclerosis undergoing inpatient rehabilitation. Neurorehabil Neural Repair 1996; 10:185-94. 22. Tusaie K, Dyer J. Resilience: a historical review of the construct. Holist Nurs Pract 2004; 18:3-8. 23. Fine SB. Resilience and human adaptability: who rises above adversity? 1990 Eleanor Clarke Slagle Lecture. Am J Occup Ther 1991; 45:493-503. 24. Cal SF, De Sá LR, Glustak ME, Santiago MB. Resilience in chronic diseases: A systematic review. Cogent Psychology 2015; 2:1024928. 268